



April 26, 2016

Integra LifeSciences Announces Initial Clinical Use of the Cadence™ Total Ankle System in the United States

PLAINSBORO, N.J., April 26, 2016 (GLOBE NEWSWIRE) -- [Integra LifeSciences Holdings Corporation](#) (NASDAQ:IART), a leading global medical technology company, today announced that the first ten procedures using the Integra® Cadence™ Total Ankle System were successfully completed by Dr. Selene Parekh and Dr. David Pedowitz.

The Cadence Total Ankle System was developed in partnership with three world leading foot and ankle surgeons - Dr. Tim Daniels (University of Toronto), Dr. David Pedowitz (Rothman Institute), and Dr. Selene Parekh (Duke University).

"This ankle has incorporated many anatomical considerations into its design," said Dr. Parekh. "It allows the surgeon to maintain more bone stock, and provides options to correctly align the ankle back to its native location. Finally, we've streamlined both the Cadence system's design and instrumentation so it's more efficient for the surgeon and surgical team."

"Ankle replacement is a technically challenging procedure. With the Cadence system, we have pared down the complexity of the instrumentation in an intuitive fashion. Simply put, this will make total ankle replacement easier, quicker and more reproducible for foot and ankle surgeons," said Dr. Pedowitz.

In 2015, Integra acquired the Salto Talaris® and Salto Talaris® XT ankle replacement products. The Cadence system's differentiated anatomic design and streamlined surgical technique will complement the proven clinical history and revision features of the Salto Talaris product line, allowing Integra to offer a complete set of options to treat the entire continuum of care as it enters one of the fastest growing extremities segments.

About Integra

Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Company

Investors

Angela Steinway
609-936-2268
angela.steinway@integralife.com

Michael Beaulieu

609-750-2827
michael.beaulieu@integralife.com

Media

Gianna Sabella
609-775-8553

gianna.sabella@integralife.com